CEO of MoonLake Immunotherapeutics (NASDAQ: MLTX) sells shares under plan

Rhea-AI Filing Summary

MoonLake Immunotherapeutics director and Chief Executive Officer Jorge Santos da Silva sold 47,775 Class A ordinary shares in an open-market transaction at a weighted average price of $20.03 per share. The sale was executed on July 1, 2026 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2026.

Following this transaction, he directly holds 2,877,118 Class A ordinary shares. The filing notes that the reported price reflects a weighted average across multiple individual trades executed between $20.00 and $20.09 per share.

Insights

Equity market and governance analyst

CEO conducts pre-planned open-market sale while retaining a large share position.

The CEO of MoonLake Immunotherapeutics, Jorge Santos da Silva, executed an open-market sale of 47,775 Class A ordinary shares at a weighted average price of $20.03 per share. This is classified as a non-derivative, open-market transaction with a clear sell direction.

The sale was carried out under a Rule 10b5-1 trading plan adopted on March 31, 2026, indicating the trades were pre-scheduled rather than timed discretionarily. After the transaction, he continues to directly own 2,877,118 shares, suggesting the sale represents only a portion of his total equity stake.

There are no remaining derivative positions disclosed in this filing, and no tax-withholding, gifts, or restructuring entries are reported. Overall, this appears to be a routine liquidity event by a senior executive under a pre-arranged plan, without additional financial metrics or forward-looking information.

Insider Trade Summary 10b5-1

Net Seller: 47,775 shares ($956,933)

Net Sell 1 txn

Insider Santos da Silva Jorge

Role Chief Executive Officer

Sold 47,775 shs ($957K)

Type	Security	Shares	Price	Value
Sale	Class A ordinary shares, par value $0.0001 per share	47,775	$20.03	$957K

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 2,877,118 shares (Direct, null)

Footnotes (1)

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.09. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 47,775 shares Weighted average sale price: $20.03 per share Post-transaction holdings: 2,877,118 shares +2 more

5 metrics

Shares sold 47,775 shares Open-market sale on July 1, 2026

Weighted average sale price $20.03 per share Class A ordinary shares sale

Post-transaction holdings 2,877,118 shares CEO direct ownership after sale

Sale price range $20.00–$20.09 per share Multiple trades comprising reported sale

Trading plan adoption date March 31, 2026 Rule 10b5-1 plan governing the sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average sale price, Class A ordinary shares

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" with transaction code "S" for the CEO."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

Class A ordinary shares financial

"security_title: "Class A ordinary shares, par value $0.0001 per share""

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:11 PM Accepted by SEC EDGAR 07/02/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Santos da Silva Jorge

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A ordinary shares, par value $0.0001 per share	07/01/2026		S(1)		47,775	D	$20.03(2)	2,877,118	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.09. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MoonLake Immunotherapeutics (MLTX) report for its CEO?

MoonLake Immunotherapeutics reported that CEO Jorge Santos da Silva sold 47,775 Class A ordinary shares in an open-market transaction. The weighted average sale price was $20.03 per share, executed across multiple trades within a narrow price range between $20.00 and $20.09.

Was the MLTX CEO’s share sale on July 1, 2026 pre-planned under a Rule 10b5-1 plan?

Yes. The CEO’s sale on July 1, 2026 was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Such plans allow pre-scheduled trades, reducing the significance of trade timing as an indication of management’s current outlook.

How many MoonLake Immunotherapeutics (MLTX) shares did the CEO hold after the reported sale?

After selling 47,775 Class A ordinary shares, the CEO directly held 2,877,118 shares. This post-transaction holding figure, reported in the filing, shows that he retains a substantial stake in MoonLake Immunotherapeutics following the open-market sale under the trading plan.

What price range did the MLTX CEO’s July 1, 2026 share sales cover?

The filing states the weighted average sale price was $20.03 per share, with individual trades executed between $20.00 and $20.09. This narrow range indicates all shares in the 47,775-share sale were transacted around the same market level on that date.

Did MoonLake Immunotherapeutics (MLTX) report any derivative exercises or tax-withholding transactions for the CEO?

No derivative exercises, tax-withholding dispositions, gifts, or restructuring transactions are reported in this Form 4. The filing discloses only a single non-derivative open-market sale of 47,775 Class A ordinary shares by the CEO, with remaining holdings of 2,877,118 shares.